奥希替尼对晚期非小细胞肺癌的治疗进展-东南大学学报医学版

奥希替尼对晚期非小细胞肺癌的治疗进展

单位：南京医科大学第二附属医院疼痛科, 江苏南京 210011

分类号：R734.2

出版年·卷·期（页码）：2020·39·第一期（85-89）

摘要：

奥希替尼是第3代选择性和不可逆的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI），疗效显著，不良反应少，最新版美国国立综合癌症网络非小细胞肺癌（NSCLC）指南已明确优先推荐奥希替尼用于携带EGFR敏感突变，或使用第1代或第2代EGFR TKI产生T790M耐药突变的晚期或转移性NSCLC患者的一线治疗。奥希替尼与早期EGFR TKI相比能够有效地穿过血脑屏障，对NSCLC脑转移患者有独到的疗效。临床试验中奥希替尼的疗效优于化疗和早期EGFR TKI，成为NSCLC靶向治疗中的一匹黑马。本文中作者就奥希替尼治疗晚期NSCLC的最新进展进行综述。

参考文献：

[1] MILLER K D,NOGUEIRA L,MARIOTTO A B,et al.Cancer treatment and survivorship statistics,2019[J].CA Cancer J Clin,2019,69(5):363-385.
[2] SHI Y,AU J S K,THONGPRASERT S,et al.A Prospective,molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J].J Thorac Oncol,2014,9(2):154-162.
[3] BARLESI F,MAZIERES J,MERLIO J P,et al.Routine molecular profiling of patients with advanced non-small-cell lung cancer:results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J].Lancet,2016,387(10026):1415-1426.
[4] ROSELL R,MORAN T,QUERALT C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361(10):958-967.
[5] MOK T S,WU Y L,THONGPRASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
[6] YU H A,ARCILA M E,REKHTMAN N,et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J].Clin Cancer Res,2013,19(8):2240-2247.
[7] YU H A,SPIRA A I,HORN L,et al.Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer:Interim results from an ongoing phase 1 study[J].J Clin Oncol,2016,34(15_suppl):9050.
[8] TAN D S W,YANG J C H,LEIGHL N B,et al.Updated results of a phase 1 study of EGF816,a third-generation,mutant-selective EGFR tyrosine kinase inhibitor (TKI),in advanced non-small cell lung cancer (NSCLC) harboring T790M[J].J Clin Oncol,2016,34(15_suppl):9044.
[9] PARK K,LEE J S,HAN J Y,et al.1300:efficacy and safety of BI 1482694 (HM61713),an EGFR mutant-specific inhibitor,in T790M-positive NSCLC at the recommended phase II dose[J].J Thorac Oncol,2016,11(4):S113.
[10] SEQUIST L V,SORIA J C,GOLDMAN J W,et al.Rociletinib in EGFR-mutated non-small-cell lung cancer[J].N Engl J Med,2015,372(18):1700-1709.
[11] CROSS D A,ASHTON S E,GHIORGHIU S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discov,2014,4(9):1046-1061.
[12] ZHOU W,ERCAN D,CHEN L,et al.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M[J].Nature,2009,462(7276):1070-1074.
[13] JÄNNE P A,YANG J C H,KIM D W,et al.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J].N Engl J Med,2015,372(18):1689-1699.
[14] YANG J,RAMALINGAM S,JÄNNE P,et al.LBA2_PR:osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC:updated phase 1 (P1) and pooled phase 2 (P2) results[J].J Thorac Oncol,2016,11(4):S152-S153.
[15] PLANCHARD D,BROWN K H,KIM D W,et al.Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers:implications for formulation,dose,and dosing frequency in pivotal clinical studies[J].Cancer Chemother Pharmacol,2016,77(4):767-776.
[16] YOSAATMADJA Y,SILVA S,DICKSON J M,et al.Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed[J].J Struct Biol,2015,192(3):539-544.
[17] VISHWANATHAN K,DICKINSON P A,BUI K,et al.Abstract B153:effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291[J].Mol Cancer Ther,2015,14(12 Supplement 2):B153.
[18] THRESS K S,PAWELETZ C P,FELIP E,et al.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J].Nat Med,2015,21(6):560-562.
[19] LE X,PURI S,NEGRAO M V,et al.Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC[J].Clin Cancer Res,2018,24(24):6195-6203.
[20] OXNARD G R,HU Y,MILEHAM K F,et al.Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib[J].JAMA Oncol,2018,4(11):1527-1534.
[21] XU J,ZHAO X T,HE D F,et al.Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype[J].J Cancer Res Clin Oncol,2018,144(8):1413-1422.
[22] RAMALINGAM S,CHENG Y,ZHOU C,et al.LBA50 mechanisms of acquired resistance to first-line osimertinib:preliminary data from the phase Ⅲ FLAURA study[J].Ann Oncol,2018,29(suppl_8):mdy424.063.
[23] PAPADIMITRAKOPOULOU V,WU Y,HAN J,et al.LBA51 analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study[J].Ann Oncol,2018,29(suppl_8):mdy424.064.
[24] AHN M J,TSAI C M,SHEPHERD F A,et al.Osimertinib in patients with T790M mutation-positive,advanced non-small cell lung cancer:Long-term follow-up from a pooled analysis of 2 phase 2 studies[J].Cancer,2019,125(6):892-901.
[25] MOK T S,WU Y L,AHN M J,et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J].N Engl J Med,2017,376(7):629-640.
[26] SORIA J C,OHE Y,VANSTEENKISTE J,et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J].N Engl J Med,2018,378(2):113-125.
[27] EICHLER A F,KAHLE K T,WANG D L,et al.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer[J].Neuro Oncol,2010,12(11):1193-1199.
[28] HATA A,KATAKAMI N.Afatinib for erlotinib refractory brain metastases in a patient with EGFR-mutant non-small-cell lung cancer:can high-affinity TKI substitute for high-dose TKI?[J].J Thorac Oncol,2015,10(7):e65-e66.
[29] LEE E,KEAM B,KIM D W,et al.Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer[J].J Thorac Oncol,2013,8(8):1069-1074.
[30] HEON S,YEAP B Y,BRITT G J,et al.Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib[J].Clin Cancer Res,2010,16(23):5873-5882.
[31] YANG J C H,KIM D W,KIM S W,et al.Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC):updated results from BLOOM,a phase Ⅰ study[J].J Clin Oncol,2016,34(15_suppl):9002.
[32] WU Y L,AHN M J,GARASSINO M C,et al.CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer:data from a randomized phase Ⅲ trial (AURA3)[J].J Clin Oncol,2018,36(26):2702-2709.
[33] ROSELL R,CARCERENY E,GERVAIS R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.
[34] PARK K,TAN E H,O'BYRNE K,et al.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7):a phase 2B,open-label,randomised controlled trial[J].Lancet Oncol,2016,17(5):577-589.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录